Artiva Biotherapeutics, Inc.
ARTV
Rank in Stocks
#16537
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm... Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Share Price
$3.86
Last synced: 2026-11-17
Market Cap
$197.64M
Change (1 day)
-2.53%
Change (1 year)
23.32%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Artiva Biotherapeutics, Inc. (ARTV)
Category
Healthcare
Operating Margin for Artiva Biotherapeutics, Inc. (ARTV)
Operating Margin as of November 2026 TTM: 0.00%
According to Artiva Biotherapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Artiva Biotherapeutics, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -26,805.58% | 29,170.12% |
| 2023 | -91.58% | -92.45% |
| 2022 | -1,213.32% | -54.40% |
| 2021 | -2,660.94% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | - |
US
|
|
| 33.87% | - |
US
|
|
| -116.04% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Artiva Biotherapeutics, Inc.'s operating margin
What was Artiva Biotherapeutics, Inc.'s operating margin in 2025?
In 2025, Artiva Biotherapeutics, Inc.'s operating margin was 0.00%, compared with -26,805.58% in 2024.
How has Artiva Biotherapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Artiva Biotherapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2024 (-26,805.58%).
How does Artiva Biotherapeutics, Inc.'s operating margin compare with similar companies?
Artiva Biotherapeutics, Inc.'s operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.